Nevro Spinal Cord Stimulator Lawsuit

Updated August 3, 2026. Nevro is unusual: it has zero FDA-classified recalls on record, yet the MAUDE database logged 2,478 adverse-event reports for its devices between January 2024 and July 2026. There is no Nevro MDL yet, but a centralization petition is pending, and Globus Medical, which acquired Nevro, is a co-defendant. There is no verdict and no settlement.

Key Takeaways

Nevro has zero FDA-classified recalls on record, the only major SCS manufacturer with none, a verified finding

Yet the FDA MAUDE database logged 2,478 adverse-event reports for Nevro devices from January 2024 to July 2026

No Nevro MDL yet; a centralization petition is pending, and Globus Medical is a co-defendant

DiToto v. Nevro (May 2026) is the most plaintiff-favorable SCS ruling found; Yusnukis and Greene were dismissed. Courts are split

The one-year filing deadline risk from the Schiltz order may apply; there is no verdict or settlement

Zero recalls, thousands of reports

The most distinctive fact about Nevro is one that cuts both ways. Nevro has no FDA-classified recall on record for its spinal cord stimulator devices, a finding we verified through several independent checks and one that sets it apart from Abbott, Boston Scientific, and Medtronic. At the same time, the FDA MAUDE adverse-event database recorded 2,478 reports for Nevro devices between January 2024 and July 2026. The absence of a recall is not the same as an absence of reported problems, and MAUDE reports are unverified complaints rather than proven defects, so both facts belong on the page.

No MDL yet, and Globus is in the case

There is no Nevro spinal cord stimulator MDL as of August 2026. A centralization petition against Nevro was filed in June 2026 and remains pending before the JPML. Globus Medical, which acquired Nevro, is named as a co-defendant in many of the cases. Until a petition is decided, Nevro cases proceed individually in the districts where they are filed.

The rulings cut both ways

Nevro has produced the sharpest split of authority in the tort. In DiToto v. Nevro, a Maryland federal judge in May 2026 allowed eight counts to proceed and held that failure-to-report claims are not preempted. That is the most plaintiff-favorable spinal cord stimulator decision found to date, and it also allowed a failure-to-train theory to proceed as ordinary negligence. On the other side, the Yusnukis and Greene cases were dismissed on preemption grounds. Both outcomes are on Nevro devices, which is why the first preemption ruling from an MDL judge is expected to be so influential.

Devices, deadline, and status

Nevro spinal cord stimulator devices reported in the litigation include the Senza, Senza II, Senza Omnia, and HFX iQ systems. On timing, the July 14, 2026 Schiltz order applied one-year state limitations periods and started the clock when a patient was advised to turn the device off or developed dramatic new symptoms, not at explant. That analysis will not apply in every state, but it makes the filing timeline more urgent than commonly advertised. There is no verdict and no settlement in spinal cord stimulator litigation against Nevro or any other manufacturer, and we do not publish projected per-case figures.

Frequently Asked Questions

Is there a Nevro spinal cord stimulator MDL?

Not yet. There is no Nevro spinal cord stimulator MDL as of August 2026, but a centralization petition against Nevro is pending before the JPML, filed in June 2026. Globus Medical, which acquired Nevro, is named as a co-defendant in many cases. The only spinal cord stimulator MDL that currently exists is MDL-3181 against Boston Scientific.

Has Nevro had any FDA recalls?

No. Nevro has zero FDA-classified recalls on record for its spinal cord stimulator devices, a finding we were able to verify several different ways. That is unusual and citable: it is the only one of the four major manufacturers with no classified recall. At the same time, the FDA MAUDE database recorded 2,478 adverse-event reports for Nevro devices between January 2024 and July 2026, so the absence of a recall is not the same as an absence of reported problems.

What have courts said in Nevro cases?

Nevro has produced rulings on both sides. In DiToto v. Nevro, a Maryland federal judge in May 2026 allowed eight counts to proceed and held that failure-to-report claims are not preempted, the most plaintiff-favorable spinal cord stimulator decision found to date. On the other side, the Yusnukis and Greene cases were dismissed on preemption grounds. Courts are genuinely split, which is why the first preemption ruling in MDL-3181 is so closely watched.

Have there been any Nevro spinal cord stimulator settlements or verdicts?

No. There has never been a jury verdict or a settlement against Nevro or Globus Medical in spinal cord stimulator product liability litigation. Any specific settlement figure circulating online is a projection with no verifiable source, and we do not publish such figures.